Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 110 | +20.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 23.6 | −3.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -1.4 | −180.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 1.91 | −2.4 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -1.89 | +7.5 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 10.63 | −24.5 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Guidance
3 of 5 judged targets kept · 14 open · verdicts reflect calls analysed to Q1 FY27.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Q1 FY27 Gross Margin | Not below 65% | Q4 FY26 | Standalone gross margin came in at 67.1%, meeting the guidance floor of 65%. | Achieved |
| Peak Net Debt (Standalone) | About INR 400 crores | Q4 FY25 | No specific update provided on standalone net debt. Management only provided consolidated figures. | Ghosted |
| Capacity Utilization (New Facilities) | 50-60% in 2 years, 80-90% in 3.5-4 years | Q4 FY25 | Management focus is on utilization and commercialization, with benefits expected from FY28, reinforcing the previously communicated slower ramp-up. | Diluted |
2 of Tarsons Products Limited's 19 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 16 more targets are in the full ledger.
Claimed
Qualified
Price
1Y: ₹290.25 on 24 Oct 2025 → ₹301.2. High ₹361.5 (17 Aug 2026), low ₹166.46 (30 Mar 2026).
Overview
close before → close after
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Guidance
3 of 5 judged targets kept · 14 open · verdicts reflect calls analysed to Q1 FY27.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Q1 FY27 Gross Margin | Not below 65% | Q4 FY26 | Standalone gross margin came in at 67.1%, meeting the guidance floor of 65%. | Achieved |
| Peak Net Debt (Standalone) | About INR 400 crores | Q4 FY25 | No specific update provided on standalone net debt. Management only provided consolidated figures. | Ghosted |
| Capacity Utilization (New Facilities) | 50-60% in 2 years, 80-90% in 3.5-4 years | Q4 FY25 | Management focus is on utilization and commercialization, with benefits expected from FY28, reinforcing the previously communicated slower ramp-up. | Diluted |
Claimed
Qualified
The full ledger
A free account opens 5 company ledgers a month. All 19 tracked commitments, with each call’s wording and source.
Call summaries
Tarsons Products Limited Q1 FY27
Tarsons Products Limited reported a healthy Q1 FY27 with strong revenue growth across domestic and export markets. However, profitability was pressured by significant raw material price increases and higher costs from new facilities. The company is nearing completion of its large CAPEX program, with benefits expected to be more visible from FY28 as utilization ramps up and operating leverage improves.
Read the full callTarsons Products Q4 FY26
Tarsons Products reported a resilient Q4 and FY26, with consolidated revenue growing 7.3% and 7.7% YoY respectively, driven by strong domestic performance. However, export business faced headwinds due to geopolitical tensions, leading to a 13.4% decline in Q4. Margins were pressured by rising raw material costs and higher depreciation from new capex, though Adjusted Cash PAT saw robust 21.4% YoY growth. The company anticipates full commissioning of its capex program in H1 FY27, expecting initial benefits from higher volumes and improved product availability.
Read the full callTarsons Products Q3 FY26
Tarsons Products reported a strong Q3 FY26 with consolidated revenue growing 12.8% YoY to INR 108 crores and adjusted cash PAT increasing 38.6% YoY to INR 31.4 crores. The company is commercializing its new Panchla facility, with bioprocess products already selling, and anticipates stronger revenue growth from FY27 onwards. Despite facing aggressive pricing in the domestic market and international trade uncertainties, Tarsons expects to benefit from new FTAs and government focus on biopharma.
Read the full callEvery analysed call
Fundamentals
Current values with the period they cover; the trend reads across the 5 fiscal years held (Mar 2021 to Mar 2026).
Financials
Net profit, year on year: −181% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 99 | 96 | 113 | 91 | 102 | 108 | 121 | 110 |
| Expenses | 74 | 66 | 76 | 67 | 75 | 76 | 87 | 84 |
| Operating profit | 25 | 30 | 37 | 25 | 27 | 32 | 34 | 26 |
| Operating margin | 25.5% | 31.0% | 32.9% | 27.0% | 26.8% | 29.2% | 28.3% | 23.6% |
| Other income | 8 | 1 | 4 | 3 | 6 | 7 | 7 | 6 |
| Interest | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 |
| Depreciation | 14 | 17 | 20 | 20 | 22 | 25 | 29 | 27 |
| Profit before tax | 15 | 8 | 16 | 3 | 6 | 8 | 6 | -1 |
| Tax rate | 30.8% | 34.7% | 34.5% | 41.3% | 40.6% | 32.9% | 27.6% | 9.1% |
| Net profit | 10 | 5 | 10 | 2 | 3 | 5 | 4 | -1 |
| EPS (₹ per share) | 1.93 | 0.99 | 1.92 | 0.33 | 0.62 | 0.95 | 0.79 | -0.27 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 301 | 283 | 296 | 392 | 423 |
| Expenses | 148 | 153 | 197 | 282 | 305 |
| Operating profit | 153 | 130 | 100 | 111 | 118 |
| Other income | 8 | 12 | 11 | 16 | 23 |
| Interest | 4 | 4 | 10 | 19 | 23 |
| Depreciation | 22 | 29 | 40 | 63 | 97 |
| Profit before tax | 135 | 109 | 61 | 45 | 22 |
| Net profit | 101 | 81 | 43 | 30 | 14 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 11 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 479 | 559 | 602 | 620 | 616 | 624 |
| Borrowings | 22 | 111 | 269 | 339 | 396 | 393 |
| Other liabilities | 33 | 46 | 90 | 111 | 141 | 158 |
| Total liabilities | 544 | 726 | 972 | 1,080 | 1,164 | 1,186 |
| Fixed assets | 189 | 225 | 336 | 536 | 583 | 733 |
| Capital work in progress | 32 | 119 | 267 | 233 | 251 | 159 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 323 | 382 | 369 | 311 | 330 | 295 |
| Total assets | 544 | 726 | 972 | 1,080 | 1,164 | 1,186 |
| Line item | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operations | 68 | 83 | 103 | 114 | 118 |
| Cash from investing | -64 | -138 | -285 | -145 | -129 |
| Cash from financing | -27 | 130 | 136 | 39 | 9 |
| Net cash flow | -23 | 75 | -47 | 8 | -2 |
| Free cash flow | 6 | -48 | -81 | -37 | -7 |
| Line item | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor days | 75 | 79 | 96 | 74 | 74 |
| Inventory days | 277 | 478 | 572 | 355 | 341 |
| Days payable | 35 | 75 | 65 | 44 | 53 |
| Cash conversion cycle | 317 | 482 | 602 | 385 | 361 |
| Working capital days | 108 | 150 | -1 | 38 | -20 |
| Return on capital employed | — | 35.0% | — | 7.0% | 5.0% |
| Dividend payout | 0.0% | 0.0% | 25.0% | 0.0% | 0.0% |
The businesses behind the company’s reported revenue.
India contributes 78.1% of reported segment revenue.
Quarter ended 30 Jun 2026 · Consolidated
₹86.11 crore
₹24.13 crore
₹0.03 crore
₹0.00 crore
| Business segment | Revenue · ₹ crore | Share |
|---|---|---|
| India | 86.11 | 78.1% |
| Germany | 24.13 | 21.9% |
| Intersegment Revenue-India | 0.03 | <0.1% |
| Rest of the World | 0.00 | 0.0% |
Share = segment revenue ÷ total segment revenue, before intersegment adjustments.
Intersegment transactions are between the company’s own businesses. Net segment revenue can differ from income-statement revenue because reporting definitions differ.
Source: FinEdge · Last checked 19 Sept 2026. Reported segment names are kept as supplied.
India shrank from 81% to 78% of revenue over the last two years.
| Segment | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| India | 81% | 80% | 83% | 78% | 79% | 78% | 80% | 78% | +20.8% |
| Germany | 19% | 20% | 17% | 22% | 21% | 22% | 20% | 22% | +20.1% |
| Intersegment Revenue-India | — | — | <1% | <1% | <1% | <1% | <1% | <1% | +200.0% |
| Rest of the World | 0% | 0% | 0% | 0% | — | 0% | — | 0% | — |
Share of reported segment revenue by quarter, consolidated basis, as filed. A quarter the company did not report is left blank, never carried forward.
See how segments are shifting across companies → Segment Shift
Ownership
Public hold 51.53% as of Sept 2026; institutions added 0.91 pts since Jun 2026.
Named in the Sep 2026 filing
Every holder of Tarsons Products Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| 26.98% | unchanged | |
| 23.42% | unchanged | |
| 20.30% | unchanged | |
| 3.15% | unchanged | |
| 0.01% | unchanged | |
| 0.01% | unchanged | |
| 0.01% | unchanged | |
| 0.01% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Free account: one company. Everything above stays public.
Write why you follow Tarsons Products Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Guides on how to read this kind of business and the numbers that matter.